These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 9517912)
1. Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode. Tignol J; Pujol-Domenech J; Chartres JP; Léger JM; Plétan Y; Tonelli I; Tournoux A; Pezous N Acta Psychiatr Scand; 1998 Feb; 97(2):157-65. PubMed ID: 9517912 [TBL] [Abstract][Full Text] [Related]
2. Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results. Kasper S; Pletan Y; Solles A; Tournoux A Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():35-9. PubMed ID: 8923125 [TBL] [Abstract][Full Text] [Related]
3. A comparative study of milnacipran and imipramine in the treatment of major depressive disorder. Lopez-Ibor JJ; Conesa A; Curr Med Res Opin; 2004 Jun; 20(6):855-60. PubMed ID: 15200743 [TBL] [Abstract][Full Text] [Related]
4. A randomised, double-blind comparison of milnacipran and imipramine in the treatment of depression. Van Amerongen AP; Ferrey G; Tournoux A J Affect Disord; 2002 Oct; 72(1):21-31. PubMed ID: 12204314 [TBL] [Abstract][Full Text] [Related]
5. A comparative study of milnacipran and paroxetine in outpatients with major depression. Sechter D; Vandel P; Weiller E; Pezous N; Cabanac F; Tournoux A; J Affect Disord; 2004 Dec; 83(2-3):233-6. PubMed ID: 15555719 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of milnacipran: an overview. Montgomery SA; Prost JF; Solles A; Briley M Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():47-51. PubMed ID: 8923127 [TBL] [Abstract][Full Text] [Related]
7. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study]. Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291 [TBL] [Abstract][Full Text] [Related]
8. Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine. Vandel P; Sechter D; Weiller E; Pezous N; Cabanac F; Tournoux A; Panconi E Hum Psychopharmacol; 2004 Dec; 19(8):585-6. PubMed ID: 15570574 [No Abstract] [Full Text] [Related]
10. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Puech A; Montgomery SA; Prost JF; Solles A; Briley M Int Clin Psychopharmacol; 1997 Mar; 12(2):99-108. PubMed ID: 9219045 [TBL] [Abstract][Full Text] [Related]
11. Milnacipran and selective serotonin reuptake inhibitors in major depression. Lopez-Ibor J; Guelfi JD; Pletan Y; Tournoux A; Prost JF Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():41-6. PubMed ID: 8923126 [TBL] [Abstract][Full Text] [Related]
12. Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender. Morishita S; Arita S Eur Psychiatry; 2003 Dec; 18(8):418-20. PubMed ID: 14680720 [No Abstract] [Full Text] [Related]
13. A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder. Sambunaris A; Bose A; Gommoll CP; Chen C; Greenberg WM; Sheehan DV J Clin Psychopharmacol; 2014 Feb; 34(1):47-56. PubMed ID: 24172209 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials. Sambunaris A; Gommoll C; Chen C; Greenberg WM Int Clin Psychopharmacol; 2014 Jul; 29(4):197-205. PubMed ID: 24667487 [TBL] [Abstract][Full Text] [Related]
15. A double-blind six months comparative study of milnacipran and clomipramine in major depressive disorder. Steen A; Den Boer JA Int Clin Psychopharmacol; 1997 Sep; 12(5):269-81. PubMed ID: 9466161 [TBL] [Abstract][Full Text] [Related]
16. Fluvoxamine versus imipramine and placebo: a double-blind comparison in depressed patients. Fabre L; Birkhimer LJ; Zaborny BA; Wong LF; Kapik BM Int Clin Psychopharmacol; 1996 Jun; 11(2):119-27. PubMed ID: 8803649 [TBL] [Abstract][Full Text] [Related]
17. Milnacipran for fibromyalgia. Dempsey J Issues Emerg Health Technol; 2008 Feb; (114):1-4. PubMed ID: 18354855 [TBL] [Abstract][Full Text] [Related]
18. Antidepressant efficacy and safety of low-dose sertraline and standard-dose imipramine for the treatment of depression in older adults: results from a double-blind, randomized, controlled clinical trial. Forlenza OV; Almeida OP; Stoppe A; Hirata ES; Ferreira RCR Int Psychogeriatr; 2001 Mar; 13(1):75-84. PubMed ID: 11352337 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic effects of the selective serotonin noradrenaline reuptake inhibitor milnacipran on depressive symptoms in patients with Alzheimer's disease. Mizukami K; Hatanaka K; Tanaka Y; Sato S; Asada T Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):349-52. PubMed ID: 19166899 [TBL] [Abstract][Full Text] [Related]